DOCSLIB.ORG

Shandong Dezhou Investment Delegation to ASEAN

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Shandong Dezhou Investment Delegation to ASEAN Shandong Dezhou Investment Delegation to ASEAN CONTENTS Social and Economic Survey of Dezhou………………………………………………………………………….2 Competitive Industry of Dezhou....…………………………………………………………………………………4 CCPIT Dezhou Branch & CCIOC Dezhou Chamber…………………………………………………………..9 Shandong Dexing Group Construction Engineering Co., Ltd…………………………………………..11 Shandong Huahai Group Co., Ltd…………………………………………………………………………………13 Shandong Xin jiekou Culturaland Creative Industrial Zone …………………………………………..15 Shandong K.D.L. Textile Co., Ltd…..………………………………………………………………………………17 Dezhou Liyuan International Co.,Ltd……………………………………………………………………………19 Dezhou Huaqiang Trade Co. Ltd.………………………………………………………………………………….21 Shandong Dexing Group Gear Logistics Co., Ltd……………………………………………………………23 Hebei Dongfang Iron Tower Co., Ltd…………………….………………………………………………………25 LiuShun Automation Equipment Co., Ltd.………………………………………………………………….....27 Dezhou Huizhong Automobile Sales Co. Ltd. ………………………………………………………………..29 Leling Derum Health Food Co., Ltd…………………………………………………………………………........31 Shandong Yichang Lighting Technology Co, Ltd……………………………………………………….......33 Shandong Jitai Welding Materials Co., Ltd……………………………………………………………………35 Shandong Derun New Material Technology Co., Ltd…………………………………….……………….37 Shandong Fuyang Biotechnology Co., Ltd ……………………………………………………………………39 Ji'nan Hua Kaiyuan Co., Ltd………………………………………………………………………………………...41 Shandong HuaQiang New Material Co., Ltd………………………………………………………………….43 China Huayang Economic and Trade Group Co., Ltd. (HuayangGroup)……………………………………………………………………………………………………….45 1 Social and Economic Survey of Dezhou 德州社会经济概况 Social and Economic Survey of Dezhou Located in the northwest of Shandong Province, north side of lower reaches of the Yellow River, Dezhou covers an area of 10356 square kilometers, with a total population of 5.7 million. There are 13 Counties, county-level Cities and Districts under its jurisdiction. With the favorable location and convenient transportation, since ancient times, Dezhou is known as “well connected transportation, gate keeper of the capital Beijing”. There are 5 high-speed rails include Beijing-shanghai high-speed rail and Qingdao-Yinchuan high-speed rail and 3highways, 5 national roads, 14 province roads in Dezhou city. The roads radiate in all directions, which makes Dezhou city be the key transportation hub of China. Dezhou‟s comprehensive economic strength is among the national top 100, comprehensive environment evaluation among the national top 50. Dezhou is a key transportation hub, with completed industry categories and rich human resources."Beijing-tianjin-hebei Region Coordinated Development Outline" formulated by State council has defined Dezhouas "one area and four bases", namely Beijing-tianjin-hebei Industry Shift Base, Science & Technology Achievements Transformation Base, High-quality Agricultural and Sideline Products Supply Base, Labor Transfer Base and an important Eco-function Area in the south of beijing-tianjin-hebei. 2 Social and Economic Survey of Dezhou 德州社会经济概况 德州社会经济概况 德州市位于山东省西北部，黄河下游北岸，现辖 13 个县市区，总面 积 10356 平方公里，总人口 570 万。 德州自古就有“九达天衢、神京门户”之称,区位优越，交通便利。 境内京沪高铁、青银高铁等 5 条铁路、3 条高速公路、5 条国道和 14 条 省道纵横交错,形成了四通八达的交通网络,是全国交通主枢纽城市。 德城市经济综合实力跻身全国百强，城市环境综合评估进入全国 50 强。德州产业门类齐全，人力资源丰富。国务院《京津冀一体化协同发 展纲要》将德州定位为“一区四基地”，即京津冀产业承接基地、科技 成果转化基地、优质农产品供应基地、劳动力输送基地和京津冀南部重 要生态功能区。 3 Competitive industry of Dezhou 德州优势产业 Competitive industry of Dezhou Equipment Manufacturing Mainly covers machine tools, large heavy equipment, auto & auto parts, railway transportation equipment, construction machinery, petroleum machinery and relevant industries. The important enterprises include Shandong Puecion，Tongyu Heavy Industry Co.,Ltd，Jingjin Group， Dezhou LiuShun Automation Equipment, Shandong Gold Phoenix , Degong machinery, United petroleum machinery and others. Green Chemical Industry Categories are coal chemical industry, Petroleum chemical industry, salt chemical industry , precision chemical industry and related industries. Important enterprises include Shandong Hualu-Hengsheng Chemical Co., Ltd., Stanley Group, Jinneng Technology, Hengyuan Petrochemical, Shihua Chemical, Yuhong New Pigment, etc. Textile and Clothing Mainly it includes cotton textiles, woolen textiles, industrial textiles and garment textile four broad categories. The important enterprise are Hengfeng Group, Huayuan, Shandong K.D.L. Textile , Dezhou Liyuan International and others. Agricultural Products (food) Processing It consists of wheat flour, vegetable oil, meat, fruit and vegetables, dairy products, beverages, condiments processing and other relevant industries. Important leading enterprises include Fada Flour, Dezhou Braised Chicken Group, Shuanglingchun Biological Technology, Leling Derun Health Food , Shuanghui Group，Feida group, Zhongjiao Yingchao Chili, 4 Dingli Group and others. New energy, energy saving and environmental protection Major sub-industries and important enterprises are: Solar energy utilization, there are Himin, Mega Energy, Hanyuan Green Energy, Shandong Yichang Lighting Technology, Hanneng, Jieyang and others; Wind power equipment, there are Tong Yu, Mega Energy, Jupiter，Huaye，Huaya， Shuangyi, ect. Ground-source heat pump, there are Grad group, Bright, Yatai group, Kinflare group, etc. New energy vehicles, there are Fulu motor, Baoya, Yogomo, CT&T, Chery, Mega Energy, Allgrand, etc. Biotechnology Major categories and important enterprises: Bio-manufacturing, the backbone enterprises are Baolingbao biology, Longlive, fuyang Biotechnology, Futian, Xingguang, Gushen, etc. Bio-medicine，there are Yuwang group, Hailian, Branden, Dezhou Deyao Pharmaceutical, Qilu antibiotics(Linyi) pharmaceutical, Salubris, etc. Bio-agriculture, focus on the development of bio-breeding，the backbone enterprises are Xinqiu， Xisen, etc. Construction, Building Materials and New Materials There are many categories in this filed, mainly include high-grade construction materials, polymer composites materials, geo-synthetics materials, inorganic non-metallic materials, inorganic heat transfer materials, new metallic materials, and carbon composites materials. The key enterprises are Hongxiang Chemical Fiber, Qunli Plastic, Dexing Group, Jitai Welding Materials , Suntone Carbon, Huaye Tungsten & Molybdenum, Dezhou Jinghua Group, etc. 5 Electronic Information Even though the electronic information industry is new in our city, but its growth is very strong. There are a group of specialty products and enterprises in financial equipment, electronic components, digital instrument cluster, integrated circuits and medical electronic fields. The important enterprise include Sanhe Electronic, Honglin Electronic，Fudden Electronic, Kehai Electronic, etc. 6 Competitive industry of Dezhou 德州优势产业 德州优势产业 纺织服装 主要包括棉纺织、毛纺织、产业用纺织品、服装家纺四大类产品体 系，重点企业有：恒丰、华源、凯地兰、利元国际等。 农副产品(食品)深加工 主要包括面粉、植物油、肉类、果蔬、乳品、饮料、调味品加工等 子行业，重点龙头企业有：发达面粉、扒鸡集团、双陵春生物科技、德 润健康、双汇食品、飞达集团、中椒英潮、鼎力枣业等。 新能源与节能环保 主要子行业和重点企业有：太阳能利用，有皇明、美格能源、汉源 绿色能源、亿昌、汉能、洁阳等企业；风电装备，有通裕、株丕特、华 业、华亚、双一等企业；地源热泵，有格瑞德、中大贝莱特、亚太、金 光等企业；新能源汽车有富路、宝雅、御捷马、喜特恩特、奇瑞、奥冠 电池等企业。 生物技术 主要子行业和重点企业有：生物制造，有保龄宝、龙力、福洋生物、 福田、星光、谷神等骨干企业；生物医药，有禹王、海利安、百多安、 德药制药、齐鲁安替(临邑)制药、信立泰等企业；生物农业，重点发展 7 生物育种，有鑫秋、希森等骨干企业。 装备制造 主要包括机床工具、大型重型成套设备、汽车及零部件、轨道交通 设备、工程机械、石油机械等子行业，重点企业有：普利森、通裕重工、 景津环保、德州六顺、金麒麟、德工机械、联合石油机械等。 绿色化工 主要分为煤化工、石油化工、盐化工、精细化工等子行业。重点企 业有：华鲁恒升、阳煤平原化工、史丹利复合肥、金能科技、恒源石化、 实华化工、宇虹新颜料等。 建筑、建材、新材料 建筑、建材、新材料产业门类较多，主要有高档建筑材料、高分子 复合材料、土工合成材料、无机非金属材料、无机传热材料、新型金属 材料、碳复合材料等，重点企业主要有：宏祥化纤、群力塑胶、德兴集 团、吉泰焊接、索通碳素、华业钨钼、晶华集团等。 电子信息 我市电子信息产业起步较晚，但增长势头强劲，在金融器材、电子 元器件、数字仪表、集成电路、医疗电子等领域培育了一批特色产品， 集聚了一批企业。重点企业有：三和、泓淋、富电、科海等。 8 CCPIT Dezhou Branch & CCIOC Dezhou Chamber 德州市贸促会 德州国际商会 CCPIT Dezhou Branch & CCIOC Dezhou Chamber CCPIT Dezhou Branch is the abbreviation of China Council for the Promotion of International Trade Dezhou Branch; CCOIC Dezhou Branch is the abbreviation of China Chamber of International Commerce Dezhou Branch. CCPIT and CCOIC implement the strategy of "one institution, two titles". Its main purposes:Ⅰaccording to international law and policy to carry out foreign trade, utilize foreign capital, introduce technology, as well as hold cooperation and exchange activities, to promote trade and economic development between China and other countries.Ⅱ Serve member enterprises, respond the demands of the enterprise, provide international exchanges, legal advice, exhibition information, dispute mediation, training, help enterprises to enhance their ability to participate in international economic and trade exchanges. Currently, owning 348 member enterprises , working with 19 the third party service institutions, CCPIT(CCOIC)Dezhou Branch has established strategic cooperative relations with41 government agencies as well as business associations from more than 20 countries and regions such as U.S.A, Germany, France, Japan, Korea, Hang Kong, Macao, and Taiwan, and has become an important channel for member enterprises‟ foreign exchanges and cooperation, a very important window of Dezhou‟s opening to the outside world. ADD:No.1566.East Dongfeng Rd., Dezhou, Shandong, China TEL:0534-2231961 EMAIL: [email protected] 9 CCPIT Dezhou Branch & CCIOC Dezhou Chamber 德州市贸促会 德州国际商会 德州市贸促会 德州国际商会 德州市贸促会、德州国际商会全称分别是中国国际贸易促进委员会 德州市支会、中国国际商会德州商会，是中国国际贸易促进委员会 （CCPIT）和中国国际商会（CCOIC）的分支机构。 贸促会和国际商会实行“一个机构，两块牌子”。其主要宗旨是：对 外根据国际法律和政策，开展对外贸易、利用外资、技术引进、合作交 流等活动，促进中国及各地方行政单位同世界各国、各地区之间的贸易 和经济关系发展。对内服务会员企业，反映企业诉求，提供国际交流、 法律咨询、信息会展、纠纷调解、培训招商，帮助企业提升参与国际经 济和贸易交流的能力。 目前，德州市贸促会、德州国际商会已发展会员企业 348 家。与美国、 德国、法国、日本、韩国等二十多个国家地区和港、澳、台等 41 个政 府机构和商协会建立了战略合作关系，在省内外社会中介、服务组织中 确定了 19 家第三方服务机构，已成为会员企业对外交流合作的重要渠 道、德州市对外开放的重要窗口。 地址：山东省德州市，东风东路
Load more

Recommended publications
  • Perillyl Alcohol Conjugate Downregulates O6-Methylguanin DNA Methltransferase Via Inducing Ubiquitination-De
    Song et al. Cell Death and Disease (2018) 9:202 DOI 10.1038/s41419-017-0193-2 Cell Death & Disease ARTICLE Open Access Temozolomide–perillyl alcohol conjugate downregulates O6- methylguanin DNA methltransferase via inducing ubiquitination-dependent proteolysis in non-small cell lung cancer Xingguo Song1,LiXie1,2,MinghuiChang2,3,XinranGeng4,XingwuWang1,ThomasC.Chen5 and Xianrang Song 1,2 Abstract The DNA repair enzyme O6-methylguanin-DNA-methltransferase (MGMT) is able to remove products of alkylating agent such as O6-meG and emerges as a central determinant of cancer resistance to temozolomide (TMZ). Temozolomide–perillyl alcohol conjugate (TMZ–POH), a novel TMZ analog developed based on the conjugation of TMZ and POH, displayed strong anticancer potency in multiple cancer types, but seemed not to experience the chemoresistance even in cells with high MGMT expression unlike TMZ and other alkylating agents. In this study, we demonstrated TMZ–POH inhibited MGMT dependent on proteasomal pathway and this inhibition is a significant factor in its toxic effect in the non-small cell lung cancer (NSCLC) cells. 1234567890():,; 1234567890():,; Introduction such as O6-methyl-guanine (O6-meG), which trigger cell Nowadays, chemotherapy has been traditionally con- cycle-dependent DNA damage and cell death4. Although sidered as one of the standard treatment options for TMZ chemotherapy may enhance survival of cancer cancer patients, but the chemoresistance dramatically patients, intrinsic or acquired resistance to TMZ is also hinders its clinical application, especially for alkylating common and accounts for many treatment failures5, agents like temozolomide (TMZ)1. TMZ, an imidazote- because TMZ-induced DNA alkylation damage can be trazine derivative of the alkylating agent dacarbazine, was repaired by O6-methylguanin-DNA-methltransferase approved by the US FDA (Food and Drug Administration) (MGMT)6.
    [Show full text]
  • Annual Report 2019 X
    CHAPTER I Definition 2 CHAPTER XI Corporate Governance Report 102 CHAPTER II Risk Warnings 5 I. Overview of Corporate Governance 102 CHAPTER III Company Profile 6 II. General Meeting 102 I. Profile 6 III. Performance of the Directors 104 II. History 9 IV. Work Performance of Board of Directors and 111 III. Staff Profile 11 Special Committees IV. Brief Introduction of the Organs and Branches 12 V. Chairman and General Manager 123 V. Basic Information about the Industry in Which the 16 VI. Securities Transactions by the Directors, Supervisors and 125 Company Operates Senior Management VI. Business Briefings of the Company 16 VII. Performance of Duties by Independent Non-executive 125 VII. Briefings of our Subsidiaries 17 Directors VIII. Honours Awarded to the Company During the 18 VIII. Supervision on Risk Management and Internal Control 125 Reporting Period System CHAPTER IV Financial Summary 20 IX. Other Relevant Matters 128 I. Major Accounting Data of the Group 20 CHAPTER XII Internal Control 133 II. Major Financial Indexes of the Group 20 I. Establishment of Internal Control Structure 133 III. Net Capital of the Company and Relevant Risk Control 21 II. Implementation and Operation of Internal Control System 133 Indicators III. Supervision and Inspection of Internal Control 133 IV. Financial Conditions of the Group of the Latest Five Years 22 IV. Conclusion of the Assessment of Internal Control 134 CHAPTER V Chairman Statement 23 CHAPTER XIII Independent Auditor’s Report 135 CHAPTER VI Management Discussion and Analysis 25 CHAPTER XIV Notes to the Consolidated Financial 140 I. Economic and Futures Market Analysis during the 25 Statements Reporting Period Consolidated Statements of Comprehensive Income 140 II.
    [Show full text]
  • SEC61G Is Upregulated and Required for Tumor Progression in Human Kidney Cancer
    MOLECULAR MEDICINE REPORTS 23: 427, 2021 SEC61G is upregulated and required for tumor progression in human kidney cancer HUI MENG1, XUEWEN JIANG1, JIAN WANG2, ZUNMENG SANG1, LONGFEI GUO1, GANG YIN1 and YU WANG3 1Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012; 2Department of Urology, People's Hospital of Laoling, Laoling, Shandong 253600; 3Reproductive Medicine Center, Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China Received December 16, 2019; Accepted January 29, 2021 DOI: 10.3892/mmr.2021.12066 Abstract. Kidney cancer is a malignant tumor of the urinary promote kidney tumor progression. Therefore, the present system. Although the 5‑year survival rate of patients with study provided a novel candidate gene for predicting the kidney cancer has increased by ~30% in recent years due to prognosis of patients with kidney cancer. the early detection of low‑grade tumors using more accurate diagnostic methods, the global incidence of kidney cancer Introduction continues to increase every year. Therefore, identification of novel and efficient candidate genes for predicting the prog‑ Kidney cancer is a malignant tumor of the urinary system, nosis of patients with kidney cancer is important. The present accounting for 2.2% of all adult malignancies worldwide (1). study aimed to investigate the role of SEC61 translocon The most common type of kidney cancer is renal cell carci‑ subunit‑γ (SEC61G) in kidney cancer. The Cancer Genome noma (RCC), which accounts for 85‑90% of all cases (2). Atlas database was screened to obtain the expression profile According to the classification of International Society of of SEC61G and identify its association with kidney cancer Urological Pathology, RCC is primarily divided into three prognosis.
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • Efficacy of Small‑Dose Ganciclovir on Cytomegalovirus Infections in Children and Its Effects on Liver Function and Mir‑UL112‑3P Expression
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 22: 912, 2021 Efficacy of small‑dose ganciclovir on cytomegalovirus infections in children and its effects on liver function and miR‑UL112‑3p expression QINGXIU WANG1*, WENZENG ZHOU2*, BIN WANG3, GUOYUN QIN4, FENG'AI LIU5, DEXIANG LIU6 and TENGTENG HAN2 1Office of Hospital Infection Management, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031; 2Department of Child Rehabilitation, Zaozhuang Maternal and Child Health Hospital of Shandong Province, Zaozhuang, Shandong 277100; 3Department of Child Rehabilitation, The Second People's Hospital of Liaocheng, Liaocheng, Shandong 252600; 4Department of Pharmacy, Yidu Central Hospital, Weifang, Shandong 262500; 5Department of Paediatrics, Haiyang People's Hospital of Shandong Province, Haiyang, Shandong 265100; 6Department of Pediatrics, Laoling People's Hospital, Laoling, Shandong 253600, P.R. China Received April 3, 2020; Accepted February 1, 2021 DOI: 10.3892/etm.2021.10344 Abstract. The aim of the study was to explore the efficacy treatment, there was also no significant difference between the of small‑dose ganciclovir on cytomegalovirus infections as two groups in miR‑UL112‑3p, TB, ALT, and AST, while after well as its effects on the liver function and miR‑UL112‑3p treatment, both groups showed lower levels of miR‑UL112‑3p, of children. A total of 141 children infected with cyto‑ TB, ALT, and AST, and the Obs group showed significantly megalovirus admitted to the Affiliated Hospital of Weifang lower levels thereof than the Con group (all P<0.05). In addi‑ Medical University from May 2015 to August 2017 were tion, the area under the curve (AUC), specificity, and sensitivity enrolled, of which 74 children were treated with small‑dose of miR‑UL112‑3p in the ROC curve of the Obs group were ganciclovir as an observation group (Obs group), and the rest 0.866, 73.77 and 84.62%, respectively, while the AUC, speci‑ were treated with conventional‑dose ganciclovir as a control ficity, and sensitivity of the ROC of the Con group were 0.837, group (Con group).
    [Show full text]
  • 2012 Annual Report 2017-10-17
    www.cs.ecitic.com (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (STOCK CODE : 6030) 2012 ANNUAL REPORT This annual report is printed on environmental paper. IMPORTANT NOTICE The Board and the supervisory committee of the Company and the Directors, Supervisors and Senior Management warrant the truthfulness, accuracy and completeness of the report and that there is no false representation, misleading statement contained herein or material omission from this report, and for which they will assume joint and several liabilities. This report was considered and approved at the 11th Meeting of the 5th Session of the Board of the Company. All Directors of the Company attended the meeting. No Director or Supervisor submitted any objection to this report. The Company’s 2012 profi t distribution proposal considered by the Board is a cash dividend of RMB3.00 for every 10 shares (tax inclusive), and is subject to the approval of the general meeting of the Company. The domestic and international annual fi nancial reports of the Company were audited by Ernst & Young Hua Ming LLP and Ernst & Young respectively, and auditor’s reports with standard unqualifi ed audit opinions were issued accordingly. Mr. WANG Dongming, Chairman of the Company, and Mr. GE Xiaobo, the person-in-charge of accounting affairs and the head of the Company’s fi nancial department, warrant that the fi nancial statements set out in this annual report are true, accurate and complete. There was no appropriation of funds of the Company by connected parties for non-operating purposes.
    [Show full text]
  • Annual Report 2019 Annual Report
    Annual Report 2019 Annual Report 2019 For more information, please refer to : CONTENTS DEFINITIONS 2 Section I Important Notes 5 Section II Company Profile and Major Financial Information 6 Section III Company Business Overview 18 Section IV Discussion and Analysis on Operation 22 Section V Directors’ Report 61 Section VI Other Significant Events 76 Section VII Changes in Shares and Information on Shareholders 93 Section VIII Directors, Supervisors, Senior Management and Staff 99 Section IX Corporate Governance Report 119 Section X Independent Auditor’s Report 145 Section XI Consolidated Financial Statements 151 Appendix I Information on Securities Branches 276 Appendix II Information on Branch Offices 306 China Galaxy Securities Co., Ltd. Annual Report 2019 1 DEFINITIONS “A Share(s)” domestic shares in the share capital of the Company with a nominal value of RMB1.00 each, which is (are) listed on the SSE, subscribed for and traded in Renminbi “Articles of Association” the articles of association of the Company (as amended from time to time) “Board” or “Board of Directors” the board of Directors of the Company “CG Code” Corporate Governance Code and Corporate Governance Report set out in Appendix 14 to the Stock Exchange Listing Rules “Company”, “we” or “us” China Galaxy Securities Co., Ltd.（中國銀河證券股份有限公司）, a joint stock limited company incorporated in the PRC on 26 January 2007, whose H Shares are listed on the Hong Kong Stock Exchange (Stock Code: 06881), the A Shares of which are listed on the SSE (Stock Code: 601881) “Company Law”
    [Show full text]
  • Original Article Changes in Neurochemical Metabolism Measured by Magnetic Resonance Spectroscopy and Expression of the ERK Sign
    Int J Clin Exp Med 2019;12(12):13592-13600 www.ijcem.com /ISSN:1940-5901/IJCEM0098210 Original Article Changes in neurochemical metabolism measured by magnetic resonance spectroscopy and expression of the ERK signaling pathway in a rat model of depression Wei Zhang1,2,3, Caixia Yang2, Xianglin Li2, Tongshen Liu2, Huiqiong Luo2, Ning Mao4, Qi Zhang2, Bin Wang1,2 1Shandong Medical Imaging Research Institute, Shandong University, No. 324, Jingwu Road, Huaiyin District, Jinan 250021, Shandong Province, China; 2Binzhou Medical University, No. 346, Guanhai Road, Laishan District, Yantai 264003, Shandong Province, China; 3Dezhou University, No. 566, Daxue West Road, Decheng District, Dezhou 253023, Shandong Province, China; 4Yantai Yuhuangding Hospital, No. 20, Yuhuangding East Road, Zhifu District, Yantai 264000, China Received June 9, 2019; Accepted October 7, 2019; Epub December 15, 2019; Published December 30, 2019 Abstract: Objective: To explore the neurochemical metabolism in the brain of rats with chronic unpredictable mild stress (CUMS) using magnetic resonance spectroscopy (MRS). Methods: All rats were anesthetized and scanned in axial, sagittal, and coronal positions with a 7.0 T MRI. The signals of N-acetylaspartate (NAA), choline-containing compounds (CHO), glutamate (GLU), and myo-inositol (MI) were determined by PRESS sequence acquisition 1H spectra in the hippocampus and prefrontal cortex. After scanning, the target antigen was detected by immunohis- tochemistry (IHC). Results: The sucrose consumption in the model group was significantly decreased compared with the control group (P<0.05). The level and vertical scores of the model group in an open field experiment were significantly lower than the control group (P<0.05).
    [Show full text]
  • The Lower Precambrian of China
    Revista Brasileira de Geociências 12(1-3): 65-73, Mar.-Set., 1982 - São Paulo THE LOWER PRECAMBRIAN OF CHINA CHENG YUQI*, DAI JlN" and SUN DAZHONG** AB5TRACT IThe Lower Precambrian of China consists of Archean and Lower Proterozoic formations formed probably prior to ca. 1,800-1,900 Ma. They are exposed chiefly in the North China Platform. Archean rocks are composed mainly of gneisses, granulitite and plagloclase-amphibolite of the amphibolite facies, with the lower part containing pyroxene-gneiss and granulite of the granu­ lite fades. The parent rocks were not well differentiated sedimentaries and volcanics, forming two volcano-sedimentary cycles. During the Archean (before 2,500-2,600 Ma), the tectonic en­ vironment over an extensive area .was quite uniform yet fairly active. Towards the end of Archean there prevailed median- to high-grade metamorphism often accompanied by rather intensive mig­ matization. ln the first Early Proterozoíc epoch, a thick sequence of volcano-sedimentaries were accumu­ lated in some marine troughs regarded as eugeosynclinal and developed on the Archean sialic basement, such as the Wutai Group. The protoliths were lhe rather widespread volcanics, the "semipelitic" and pelitic types and turbidites, mainly of greenschisr fades and partly amphibolite facies, occasionally accompanied by migmatization probably not later than 2,300 Ma. After that, a stratigraphic pile accumulated in the miogeosynclinal basins or troughs as rep­ resented by lhe HutuoGroup, and was composed of coarser clastics. pelitics and stromatclite­ -bearing Mg-rich carbonates which show rhythmic deposition. Their greenschist metamorphism probably occurred during ca. I ,800~1 ,900 Ma and this marked the end of the Early Precambrian history.
    [Show full text]
  • Store Name：Microsoft Authorized Store Store ID: AR106 Contact
    Store Name：Microsoft Authorized Store Store ID: AR106 Contact Name: Deng Hongbo Phone: 18953380824 Address: Floor 5, ZiBo Shopping Store, No.125 JinJing Street, ZhangDian District, Zibo, Shandong Province Postal Code: 255000 Store Name：Microsoft Authorized Store -Shandong Yinhao Information Technology Co., Ltd Store ID: AR146 Contact Name: Zheng Chenxiao Phone: 13370514476 Address: Q2007 Microsoft Store, No.1 gate of Huaqiang electronic world, Shanda Road, Lixia District, Jinan City Postal Code: 250013 Store ID: DSD01 Contact Name: Liu Jianqi Phone: 0534-2444111 Address: North Campus of No.5 Middle School, Lujia Street, Decheng District, Dezhou City, 100 meters to the east of the road Postal Code: 253000 Store ID: DSD02 Contact Name: Zhang Yu Phone: 0546-8555163 Address: No. 28, Xisan Road, Dongying District, Dongying City (2nd floor, 20 meters north of Industrial and Commercial Bank of North China, intersection of Xisan Road and Jinan Road) Postal Code: 257061 Store ID: DSD05 Contact Name: Xia Yang Phone: 0531-86421116 Address: Rm. 1115, Keyuan Building, Shanda Road Postal Code: 250014 Store ID: DSD06 Contact Name: Long Maoqiang Phone: 0537-2905079 Address: Jinyu road and road intersection southwest corner of pipa Postal Code: 272100 Store ID: DSD07 Contact Name: Yan Jiabao Phone: 0539-8367282 Address: West of Cross road of Tongda Road Postal Code: 276000 Store ID: DSD08 Contact Name: Geng Haifeng Phone: 0532-80687682 Address: Rm. 1507, Yinjie Shouzuo,153 Liaoning Road Postal Code: 266300 Store ID: DSD09 Contact Name: Liu Wei Phone: 0538-8251091 Address: West Xiaheqiao, Caiyuan Ave. Postal Code: 271000 Store ID: DSD10 Contact Name: Liu Chengkai Phone: 0536-2996911 Address: North Temple Street Broadcasting Digital Plaza, six floor 619 Postal Code: 261041 Store ID: DSD11 Contact Name: Lu Haiying Phone: 0631-5285566 Address: No.
    [Show full text]
  • 中國內地指定醫院列表 出版日期: 2019 年 7 月 1 日 Designated Hospital List in Mainland China Published Date: 1 Jul 2019
    中國內地指定醫院列表 出版日期: 2019 年 7 月 1 日 Designated Hospital List in Mainland China Published Date: 1 Jul 2019 省 / 自治區 / 直轄市 醫院 地址 電話號碼 Provinces / 城市/City Autonomous Hospital Address Tel. No. Regions / Municipalities 中國人民解放軍第二炮兵總醫院 (第 262 醫院） 北京 北京 西城區新街口外大街 16 號 The Second Artillery General Hospital of Chinese 10-66343055 Beijing Beijing 16 Xinjiekou Outer Street, Xicheng District People’s Liberation Army 中國人民解放軍總醫院 (第 301 醫院） 北京 北京 海澱區復興路 28 號 The General Hospital of Chinese People's Liberation 10-82266699 Beijing Beijing 28 Fuxing Road, Haidian District Army 北京 北京 中國人民解放軍第 302 醫院 豐台區西四環中路 100 號 10-66933129 Beijing Beijing 302 Military Hospital of China 100 West No.4 Ring Road Middle, Fengtai District 中國人民解放軍總醫院第一附屬醫院 (中國人民解 北京 北京 海定區阜成路 51 號 放軍 304 醫院） 10-66867304 Beijing Beijing 51 Fucheng Road, Haidian District PLA No.304 Hospital 北京 北京 中國人民解放軍第 305 醫院 西城區文津街甲 13 號 10-66004120 Beijing Beijing PLA No.305 Hospital 13 Wenjin Street, Xicheng District 北京 北京 中國人民解放軍第 306 醫院 朝陽區安翔北里 9 號 10-66356729 Beijing Beijing The 306th Hospital of PLA 9 Anxiang North Road, Chaoyang District 中國人民解放軍第 307 醫院 北京 北京 豐台區東大街 8 號 The 307th Hospital of Chinese People’s Liberation 10-66947114 Beijing Beijing 8 East Street, Fengtai District Army 中國人民解放軍第 309 醫院 北京 北京 海澱區黑山扈路甲 17 號 The 309th Hospital of Chinese People’s Liberation 10-66775961 Beijing Beijing 17 Heishanhu Road, Haidian District Army 中國人民解放軍第 466 醫院 (空軍航空醫學研究所 北京 北京 海澱區北窪路北口 附屬醫院） 10-81988888 Beijing Beijing Beiwa Road North, Haidian District PLA No.466 Hospital 北京 北京 中國人民解放軍海軍總醫院 (海軍總醫院） 海澱區阜成路 6 號 10-66958114 Beijing Beijing PLA Naval General Hospital 6 Fucheng Road, Haidian District 北京 北京 中國人民解放軍空軍總醫院 (空軍總醫院） 海澱區阜成路 30 號 10-68410099 Beijing Beijing Air Force General Hospital, PLA 30 Fucheng Road, Haidian District 中華人民共和國北京市昌平區生命園路 1 號 北京 北京 北京大學國際醫院 Yard No.1, Life Science Park, Changping District, Beijing, 10-69006666 Beijing Beijing Peking University International Hospital China, 東城區南門倉 5 號(西院) 5 Nanmencang, Dongcheng District (West Campus) 北京 北京 北京軍區總醫院 10-66721629 Beijing Beijing PLA.
    [Show full text]
  • Annual Report
    2019 ANNUAL REPORT (A joint stock company incorporated in the People’s Republic of China with limited liability) (H Shares Stock Code: 3866) (Preference Shares Stock Code: 4611) 2019 Contents Section I Important Notice, Contents and Definitions 3 Section II Corporate Information and Key Financial Highlights 6 Section III Chairman’s Statement 13 Section IV President’s Statement 14 Section V Business Overview 15 Section VI Discussion and Analysis of Operations 18 Section VII Significant Events 78 Section VIII Changes in Share Capital and Information on Shareholders 95 Section IX Preference Shares 105 Section X Directors, Supervisors, Senior Management and Employees 108 Section XI Corporate Governance 126 Section XII Report of the Board of Directors 150 Section XIII Report of the Board of Supervisors 157 Section XIV Independent Auditor’s Report 158 Section XV Financial Statements and Notes 165 Section XVI Unaudited Supplementary Financial Information 282 Bank of Qingdao Co., Ltd. 2 2019 Annual Report Section I Important Notice, Contents and Definitions 1. The Board of Directors, Board of Supervisors, Directors, Supervisors and senior management of the Bank assure that the information in this annual report contains no false records, misleading statements or material omissions, and severally and jointly take full responsibility for the authenticity, accuracy and completeness of the information in this annual report. 2. The proposals on the 2019 Annual Report of Bank of Qingdao Co., Ltd. and its summary were considered and approved at the 33rd meeting of the seventh session of the Board of Directors of the Bank held on 20 March 2020. There were 14 Directors eligible for attending the meeting, of whom 14 Directors attended the meeting.
    [Show full text]